Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
نویسندگان
چکیده
منابع مشابه
Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.
HCV associated liver disease continues to be the most common indication for liver transplantation in the West. Although the impact of HCV infection varies substantially between recipients, allograft failure secondary to recurrence of HCV infection is the most frequent cause of death and graft failure in HCV infected recipients. Attenuating the impact of HCV on posttransplant patient and graft s...
متن کاملFactors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
AIM To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency virus-positive patients and patients who received a liver transplant were excluded. Fac...
متن کاملRenal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
UNLABELLED In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse event. The PAN study is a noninterventional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or without TVL or BOC. Here we restrict the analysis to hepatitis C virus genotype 1 patients having completed 12 (n = 895) or 24 weeks (n ...
متن کاملTreatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virolog...
متن کاملBoceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates. The addition of direct-acting antiviral agents, telaprevir (TVR) or boceprevir to pegylated interferon (PEG-IFN) and ribavirin (RBV) represents a new era of therapy associated with an improvement in treatment response rates and an impairment ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista do Instituto de Medicina Tropical de São Paulo
سال: 2018
ISSN: 1678-9946
DOI: 10.1590/s1678-9946201860029